Consistent with our previous studies of CpG or GM-CSF single administration [11, 12], we found significantly higher levels of MAA-specific CD8+ T cell rates in tumor-negative SLNs of combined low-dose CpG and GM-CSF-administered patients compared to the tumor-negative control group (Fig. 4b). The gene discussed is CSF2; the disease is neoplasm.